Entrada TherapeuticsTRDA +4.15%23 PS Ratio is 57.28 as of Jul. 02, 2026, which is 1399% above its 10-year median of 3.82. GuruFocus rates TRDA with a GF Score™ of 23/100 and a GF Value™ of $0.95 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 933 Biotechnology companies, Entrada Therapeutics ranks worse than 79.1% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Entrada Therapeutics's share price is $7.905.
Entrada Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.14. Hence, Entrada Therapeutics's PS Ratio for today is 57.28.
The historical rank and industry rank for Entrada Therapeutics's PS Ratio or its related term are showing as below:
TRDA'
s PS Ratio Range Over the Past 10 Years
Min: 1.53 Med: 3.82 Max: 105.07
Current: 57.28
During the past 7 years, Entrada Therapeutics's highest PS Ratio was 105.07. The lowest was 1.53. And the median was 3.82.
TRDA's PS Ratio is ranked worse than 79.1% of 933
companies
in the Biotechnology industry
Industry Median: 9.46
vs TRDA: 57.28
Entrada Therapeutics (NAS:TRDA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Entrada Therapeutics PS Ratio Related Terms
Entrada Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Entrada Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Entrada Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entrada Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Entrada Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Entrada Therapeutics's Share Price of today is $7.905. Entrada Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.14.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Entrada Therapeutics (TRDA) has a PS Ratio of 57.28 as of Jul. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Entrada Therapeutics and its competitors. This is 1399% above median its historical median of 3.82. Over the past decade, Entrada Therapeutics' PS Ratio has ranged from 1.53 to 105.07. According to the industry distribution chart, Entrada Therapeutics ranks #738 out of 933 companies in the Biotechnology industry, placing it in the top 79.1%.
Is Entrada Therapeutics' PS Ratio too high?
Entrada Therapeutics' current PS Ratio of 57.28 is 1399% above median its 10-year median of 3.82. Over the past 10 years, this metric has ranged from a low of 1.53 to a high of 105.07. The Biotechnology industry median PS Ratio is 9.46. Entrada Therapeutics' value of 57.28 is 505.5% above this industry median. Based on the distribution chart, Entrada Therapeutics ranks #738 out of 933 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Entrada Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Entrada Therapeutics' PS Ratio compare to NMRA and MGNX?
According to the Biotechnology industry distribution chart, Entrada Therapeutics ranks #738 out of 933 companies for PS Ratio. This places Entrada Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.46. Entrada Therapeutics' value of 57.28 is 505.5% above this benchmark. Historically, Entrada Therapeutics' own PS Ratio has ranged from 1.53 to 105.07 over the past decade. While the company's 10-year median is 3.82 vs. the industry median of 9.46, Entrada Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.46, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Entrada Therapeutics's current PS Ratio of 57.28 is 505.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Entrada Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entrada Therapeutics's current PS Ratio is 57.28, which is 1399% above median its own 10-year median of 3.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entrada Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Entrada Therapeutics (TRDA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.95, compared to a current price of $7.91 — trading 732.1% above its estimated fair value. The current PS Ratio is 57.28, which is 1399% above median its 10-year median of 3.82 and 505.5% above the Biotechnology industry median of 9.46. Entrada Therapeutics' overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Entrada Therapeutics (TRDA), the current PS Ratio is 57.28 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Entrada Therapeutics (TRDA) Overvalued in 2026?
Based on GuruFocus' analysis, Entrada Therapeutics stock appears to be overvalued.
The current stock price of $7.91 is trading 732.1% above its estimated GF Value™ of $0.95.
GuruFocus considers Entrada Therapeutics to be Significantly Overvalued.
Key valuation signals for TRDA:
PS Ratio: 57.28 (1399% above median its 10-year median of 3.82)
GF Value™: $0.95 vs. price of $7.91 (732.1% above fair value)
Industry Position: 505.5% above the Biotechnology median (#738 of 933)
No single metric tells the full story. See the TRDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
23GF Score
Get the complete analysis for TRDA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRDA has been successfully added to your 
